Sickle Cell Clinical Trials

173 recruitingLast updated: July 25, 2026

There are 173 actively recruiting sickle cell clinical trials across 42 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Chicago, Illinois, United States, Memphis, Tennessee, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Sickle Cell Trials at a Glance

173 actively recruiting trials for sickle cell are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Not Applicable with 53 trials, with the heaviest enrollment activity in Chicago, Memphis, and Atlanta. Lead sponsors running sickle cell studies include St. Jude Children's Research Hospital, Children's Hospital Medical Center, Cincinnati, and Assistance Publique - Hôpitaux de Paris.

Browse sickle cell trials by phase

Treatments under study

About Sickle Cell Clinical Trials

Looking for clinical trials for Sickle Cell? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Sickle Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Sickle Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 173 trials

Recruiting
Phase 1

Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

Sickle Cell Disease, Hemolytic Anemia
National Heart, Lung, and Blood Institute (NHLBI)25 enrolled1 locationNCT07566494
Recruiting

Blood Sampling for Research Related to Sickle Cell Disease

Sickle Cell DiseaseSickle Cell TraitSickle Cell Anemia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)250 enrolled1 locationNCT00542230
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Sickle Cell Disease
Novartis Pharmaceuticals354 enrolled32 locationsNCT06439082
Recruiting
Phase 2

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

Sickle Cell Disease
St. Jude Children's Research Hospital45 enrolled1 locationNCT07616154
Recruiting
Phase 1

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Sickle Cell Disease
City of Hope Medical Center20 enrolled1 locationNCT05384756
Recruiting
Phase 1Phase 2

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Sickle Cell Disease
Novartis Pharmaceuticals161 enrolled9 locationsNCT06546670
Recruiting

Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease

Sickle CellPKLR VariantsAdenosine Triphosphate Activities
National Heart, Lung, and Blood Institute (NHLBI)800 enrolled1 locationNCT03685721
Recruiting
Phase 2

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

Sickle Cell DiseaseOsteonecrosisAvascular Necrosis+2 more
University of California, Davis30 enrolled1 locationNCT06016634
Recruiting
Phase 1Phase 2

Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

Sickle Cell DiseaseSickle Cell Anemia in Children
Children's Hospital Medical Center, Cincinnati250 enrolled1 locationNCT07708714
Recruiting
Not Applicable

Early Life Exposures Among Children With Sickle Cell Disease

Sickle Cell DiseaseBreastfeedingAdverse Childhood Experiences
University of Alabama at Birmingham20 enrolled1 locationNCT05377372
Recruiting
Phase 2

Tocilizumab for Acute Chest Syndrome

Sickle Cell DiseaseAcute Chest Syndrome
University of Chicago200 enrolled1 locationNCT05640271
Recruiting

Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies

Mortality in Sickle CellSickle Cell Cardiopulmonary ComplicationsSickle Cell Organ Damage+2 more
National Heart, Lung, and Blood Institute (NHLBI)200 enrolled1 locationNCT05213572
Recruiting

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

ThrombophiliaThrombosisSickle Cell Disease+10 more
American Thrombosis and Hemostasis Network3,000 enrolled71 locationsNCT04398628
Recruiting
Phase 1Phase 2

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

Beta-ThalassemiaSickle Cell Disease
National Heart, Lung, and Blood Institute (NHLBI)90 enrolled1 locationNCT07599176
Recruiting
Phase 3

Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease

Vaso-Occlusive Pain Episode in Sickle Cell Disease
Nantes University Hospital104 enrolled11 locationsNCT07274254
Recruiting

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

Sickle Cell DiseaseMalariaAlpha and Beta Thalassemia+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT03937817
Recruiting
Not Applicable

mAnaging siCkle CELl disEase Through incReased AdopTion of hydroxyurEa in Nigeria

Sickle Cell Disease
New York University900 enrolled1 locationNCT06318143
Recruiting
Phase 2

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Sickle Cell Disease
University of Illinois at Chicago50 enrolled1 locationNCT03121001
Recruiting
Phase 1

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Sickle Cell DiseaseHb-SS DiseaseHemoglobin S+3 more
National Heart, Lung, and Blood Institute (NHLBI)25 enrolled1 locationNCT05904093
Recruiting
Phase 1Phase 2

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Diamond-Blackfan AnemiaSickle Cell Anemiabeta thalassemia major
Paul Szabolcs5 enrolled1 locationNCT03653338